A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibodyChad J. Swanson, Jeffrey L. Cummings, June Kaplow et al.|Alzheimer s Research & Therapy|2021Cited by 818
Design of a Bayesian adaptive phase 2 proof‐of‐concept trial for BAN2401, a putative disease‐modifying monoclonal antibody for the treatment of Alzheimer's diseaseAndrew Satlin, Donald A. Berry, Jinping Wang et al.|Alzheimer s & Dementia Translational Research & Clinical Interventions|2016Cited by 87